Table. Survival Outcomes According to Gene Expression Signatures Across Treatment Cohorts in Patients With Gene Expression Dataa.
| Treatment Group | Progression-Free Survival | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Immune | Cell Cycle | HR (95% CI)b | P Value | Immune | Cell Cycle | HR (95% CI)b | P Value | |
| All pooled patients (n = 608) | 7.39 (6.70-8.97) | 5.42 (4.44-6.54) | 0.75 (0.62-0.89) | .002 | 18.83 (15.61-23.16) | 13.31 (11.30-15.24) | 0.74 (0.61-0.90) | .002 |
| Cobimetinib plus vemurafenib (n = 143) | 12.94 (9.69-20.34) | 10.51 (7.92-13.50) | 0.76 (0.50-1.17) | .21 | 27.96 (21.49-NE) | 21.55 (17.54-31.08) | 0.71 (0.44-1.14) | .16 |
| Vemurafenib (n = 320) | 7.84 (6.97-9.56) | 5.55 (4.80-6.74) | 0.70 (0.54-0.90) | .01 | 18.76 (15.51-25.56) | 12.29 (10.05-14.09) | 0.74 (0.56-0.98) | .04 |
| Dacarbazine (n = 145) | 1.74 (1.48-3.12) | 1.63 (1.48-2.10) | 0.72 (0.51-1.03) | .07 | 11.14 (7.66-17.84) | 9.63 (7.26-13.31) | 0.70 (0.48-1.03) | .07 |
Abbreviation: HR, hazard ratio.
a
Unless otherwise indicated, data are reported as median (95% CI) survival time measured in months.
b
Adjusted HR for immune vs cell cycle.